TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed: review update - January 2012
Technology Appraisal no 181; Pemetrexed for the first-line treatment of non-small-cell lung cancer
Decision to defer the review
As you may be aware the planned date for review of the above guidance was June 2010. In May 2011 NICE informed stakeholders that whilst considering a proposal for a review of TA181, NICE became aware of an independent Health Technology Assessment (HTA) report on ‘First-line therapy for adult patients with non-small-cell lung cancer’ that is currently being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University. This HTA was anticipated to publish in mid 2011. Therefore NICE felt it appropriate to defer the consideration of the review until mid 2011 as it was felt that the results of the HTA report will have a significant impact upon the consideration to review TA181.
Since that decision was taken in May 2011, the publication of the HTA has experienced delays. As a consequence, we have decided to defer the consideration of the review of the guidance again to allow for the HTA to publish. It is anticipated that NICE will issue a review proposal for consultation within 6 months of publication of the HTA.
This page was last updated: 12 January 2012